Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes.

Most of the activities of IFN-gamma are the result of STAT1-mediated transcriptional responses. In this study, we show that the BRCA1 tumor suppressor acts in concert with STAT1 to differentially activate transcription of a subset of IFN-gamma target genes and mediates growth inhibition by this cytokine. After IFN-gamma treatment, induction of the cyclin-dependent kinase inhibitor, p21WAF1, was synergistically activated by BRCA1, whereas the IRF-1 gene was unaffected. Importantly, the differential induction of p21WAF1 was impaired in breast cancer cells homozygous for the mutant BRCA1 5382C allele. Biochemical analysis illustrated that the mechanism of this transcriptional synergy involves interaction between BRCA1 aa 502-802 and the C-terminal transcriptional activation domain of STAT1 including Ser-727 whose phosphorylation is crucial for transcriptional activation. Significantly, STAT1 proteins mutated at Ser-727 bind poorly to BRCA1, reinforcing the importance of Ser-727 in the recruitment of transcriptional coactivators by STAT proteins. These findings reveal a novel mechanism for BRCA1 function in the IFN-gamma-dependent tumor surveillance system.

[1]  Ralph Scully,et al.  Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.

[2]  R. Aebersold,et al.  Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Pledger,et al.  Interferon inhibits the establishment of competence in Go/S-phase transition. , 1986, Science.

[4]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[5]  H. Hanafusa,et al.  Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Sharp,et al.  DNA topology and a minimal set of basal factors for transcription by RNA polymerase II , 1993, Cell.

[7]  J. Darnell,et al.  Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex , 1996, Molecular and cellular biology.

[8]  J. Parvin,et al.  Factors associated with the mammalian RNA polymerase II holoenzyme. , 1998, Nucleic acids research.

[9]  T. Ouchi,et al.  BRCA1 regulates p53-dependent gene expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Holt.  Breast Cancer Genes: Therapeutic Strategies , 1997, Annals of the New York Academy of Sciences.

[11]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[12]  C. Glass,et al.  Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[14]  J. Darnell,et al.  Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. , 1997, Nucleic acids research.

[15]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[16]  Eugene V. Koonin,et al.  …Functional motifs… , 1996, Nature Genetics.

[17]  J. Taylor‐Papadimitriou,et al.  Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth , 1978, Nature.

[18]  Z. Wen,et al.  Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase , 1997, Molecular and cellular biology.

[19]  B. Chait,et al.  Ser727‐dependent recruitment of MCM5 by Stat1α in IFN‐γ‐induced transcriptional activation , 1998 .

[20]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[21]  G. Stark,et al.  Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon‐alpha and ‐gamma signal transduction pathways. , 1993, The EMBO journal.

[22]  J. Parvin,et al.  Activation of Transcription in Vitro by the BRCA1 Carboxyl-terminal Domain* , 1999, The Journal of Biological Chemistry.

[23]  Takashi Miyata,et al.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes , 1989, Cell.

[24]  F. Balkwill,et al.  Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells , 1977, International journal of cancer.

[25]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[26]  H. Ruffner,et al.  CBP/p300 interact with and function as transcriptional coactivators of BRCA1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[28]  J. Darnell,et al.  Two contact regions between Stat1 and CBP/p300 in interferon γ signaling , 1996 .

[29]  J. Darnell,et al.  A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. , 1995, Genes & development.

[30]  Y. Houvras,et al.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl , 1997, Nature.

[31]  C. Prives,et al.  Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.

[32]  R. Young,et al.  BRCA1 is a component of the RNA polymerase II holoenzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Stark,et al.  High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Hongbing Zhang,et al.  BRCA1, BRCA2, and DNA Damage Response: Collision or Collusion? , 1998, Cell.

[35]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Parvin,et al.  BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A , 1998, Nature Genetics.

[37]  M. King,et al.  A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  I. Verma,et al.  Transcriptional activation by BRCA1 , 1996, Nature.

[39]  J. Darnell,et al.  The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein , 1996, Journal of virology.

[40]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[41]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[42]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[43]  U. Ramsperger,et al.  p53‐catalyzed annealing of complementary single‐stranded nucleic acids. , 1993, The EMBO journal.

[44]  G. Stark,et al.  Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway , 1989, Molecular and cellular biology.

[45]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .